

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sommadosi <i>et al.</i>	Confirmation No.:	1388
Serial No.:	10/602,691	Art Unit:	1623
Filed:	June 20, 2003	Examiner:	T. McIntosh III
For:	METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS	Attorney Docket No:	11874-043-999
		(CAM:	417451-999043)
			IDX 1007 CON 1

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari ("the owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of U.S. Patent Nos. 6,812,219; 7,148,206; and 7,105,493 ("the reference patents"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the reference patents.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the reference patents in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference patents in Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari is demonstrated by virtue of assignments recorded July 12, 2001 at reel 011974 frame 0132; September 13, 2001 at reel

LAI-2997242v1



012162 frame 0294; and August 19, 2002 at reel 013193 frame 0841.

The undersigned hereby confirms that he has reviewed the assignments and, to the best of his knowledge and belief, title is in the assignees seeking to take action in this matter and that he is empowered to act on behalf of Idenix Pharmaceuticals, Inc. and Università Degli Studi Di Cagliari.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:

Position:

Università Degli Studi Di Cagliari

Date: 19 MARZO 2009 By: _____

Name:

IL RETTORE

Position: **(Pasquale Mistrretta)**

